Africa is the cradle of our species, as well as the home of most of our genetic variety and a fl ashpoint for many of today's health challenges. And yet, science has been slow to direct its resources towards this continent. This reluctance became clear with the rapid growth of human genome research after the millennium, which only belatedly expanded to cover the diversity found in African populations (Curr. Biol. (2011) 
21, R481-R484).
A decade after the fi rst sequencing of the human genome, two initiatives were launched to bring Africa into the genomic fold while building capacity in situ. One of them is the South African Genomes Programme, led by Michael Pepper at the University of Pretoria and Michele Ramsay at the University of Witwatersrand. It has recently reported full genomes of 24 individuals from diverse ethnolinguistic backgrounds, as a starting point to study genetic diversity in South Africa and establish medical association studies (Nat. Commun. (2017 ) 8, 2062 , https//doi. org/10.1038 .
The other major project based in Africa is the Human Heredity and Health in Africa initiative (H3Africa; www.h3africa.org), launched in partnership between the African Society of Human Genetics (AfSHG), the Wellcome Trust in the UK, and the National Institutes of Health in the USA.
In 2017, H3Africa was awarded new round of funding for another 5 years. It has already been successful in building research capacity and establishing 16 different genome projects and three African biobanks, in which all principal investigators are Africans and most samples stay in Africa. Crucially, in this initiative, decisions about future use of samples and data are made by the Data and Biospecimens Access Committee, which is based in Africa.
Other organisations aiming to foster research capacity in Africa include the Alliance for Accelerating Excellence in Science in Africa (AESA; http://aesa.ac.ke/), which was set up in 2015. It distributes funds that the Wellcome Trust and the Bill and Melinda Gates foundation dedicate to Africa, including parts of the funding for H3Africa, and also serves as a think-tank for scientifi c development in Africa.
The genome efforts have also improved the knowledge about genetic diversity and the genetic susceptibility to tropical diseases. However, the application of genetics to psychiatry has yet to be established in Africa and other parts of the developing world.
A gap in our knowledge
In the culture of 20 th century science, shaped fi rst by Europeans and then
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Mind the genome diversity gap
After genomic research has gradually expanded to cover human populations from around the world, psychiatric genetics still has some catching up to do. A new project aims to remove the imbalance and build research capacity in lower and middle income countries. Michael Gross reports.
also by North Americans of European origin, there has always been the default position that the standard human being is a male of European origin. This bias is refl ected in many manifestations of science, from textbooks of anatomy through to the fi rst dozens of humans who had their genomes sequenced in the fi rst decade of this century.
This selectivity is not only at odds with the actual genetic diversity of the human species, it can also easily lead to public health problems if, for instance, medical procedures and drugs are developed on a scientifi c basis that has only been established for a small subset of the human race.
"The data diversity gap yawns particularly large for neuropsychiatric and neurodevelopmental disorders, contributing to disparities in therapies available for schizophrenia, bipolar disorder, autism, and other diagnoses around the world," notes Tom Ulrich on the website of the Broad Institute at Cambridge, Massachusetts, USA. This is why the Stanley Center at the Broad Institute has launched the Stanley Global Neuropsychiatric Genetics Initiative, which aims to address the diversity gap with a range of research programmes, starting in Africa. The first to get underway is the Neuropsychiatric Genetics in African Populations (NeuroGAP) programme with its psychosis project, which is now recruiting participants in Uganda and Kenya. Three additional sites in Ethiopia, Kenya and South Africa are poised to start recruitment by April. Across all four countries, saliva samples will be collected from a total of 17,000 people with bipolar disorder or schizophrenia, and from an equal number of healthy controls.
In contrast to the H3Africa policy of conducting all research in situ, however, DNA from this study will be shipped to the Broad Institute for sequencing and further analysis. Such arrangements are always a sensitive issue in developing countries, where the export of samples can recall memories of colonial exploitation. Some countries such as Zambia have already legislated to prevent the export of such samples, whereas in countries like Uganda and Ethiopia, export of samples needs to be carefully justifi ed and needs to happen in line with capacity building efforts.
The Stanley Center has committed to sharing the data openly with the African researchers involved in leading these studies and is already running a training programme called GINGER (for Global Initiative for Neuropsychiatric Genetics Education in Research) aimed at young researchers with a proven interest in psychiatric illness, who are trained at the Broad Institute for two years. "This closes a gap left by H3Africa, which never quite had the funds to train young researchers on this scale and in such an organised fashion," says Jantina de Vries, a biomedical ethicist at the University of Cape Town, South Africa, who is involved in ethics work accompanying the project.
De Vries and also Oxford-based bioethicist Ilina Singh will be involved closely with the Stanley studies through an ethics working group composed of African bioethicists under the joint leadership of Dorcas Kamuya from KEMRI Wellcome Trust (KWTRP) Kenya and Adamu Addissie from Addis Ababa University, Ethiopia. Ethical concerns around patient consent and the fear of exploitative approaches are at the forefront of such projects. In the course of the H3Africa project, a policy framework on the ethical approach to such collaborations was developed (Trends Genet. (2015) 31, 117-119). Crucial components of this framework are the centrality of African leadership and capacity building. "This framework should broadly apply to all these projects such as NeuroGAP as well," says De Vries. "The H3Africa experience has already helped NeuroGAP researchers negotiate more favourable terms for data access, with an embargo period during which they can lead and publish their analyses together with researchers at the Broad."
A second research effort, the NeuroDEV project still in its preparation phase, aims to address neurodevelopmental disorders of childhood in African populations. This study is set to enrol children aged 3-17 with a host of neurodevelopmental conditions including autism spectrum disorders, intellectual disability, epilepsy and attention defi cit and hyperactivity disorder (ADHD). Recruitment for this study is poised to start in Kenya and South Africa in the next few weeks. Controls from a comparable geographic and ethnic background, as well as family members of affected children, will also be studied. As for psychiatric illness, there is currently little evidence about the prevalence and causation of neurodevelopmental conditions in Kenya and South Africa, and the study will contribute valuable insight into these conditions.
In the context of NeuroDEV, which will generate cell lines from selected samples for further study, the Stanley Center has agreed to make these resources available free of charge (including courier fees) to researchers based at the institutions in which samples were collected for a period of fi ve years. "This is a major step in ensuring that African researchers and institutions benefi t from genomics research collaborations such as NeuroGAP and NeuroDEV, and demonstrates the commitment of the whole team to building scientifi c capacity at local institutions," says Kirsty Donald from the University of Cape Town, who leads the South African part of NeuroDEV.
Meanwhile, psychiatric care across Africa remains dramatically underresourced, even compared with medical provisions in other fi elds such as malaria care. Psychiatrist Allen Frances, formerly of Duke University, USA, and chair of the taskforce that prepared the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM IV), is sceptical of the benefi ts of the Stanley project. "Africa has desperate needs for psychiatric services," Frances says. "Genetic studies will provide no clinical benefi t to anyone anywhere, probably for decades. If the Stanley Foundation really cares about the welfare of the mentally ill in Africa, its money could be spent in a more practical and useful way." On the plus side, however, Frances acknowledges that genetic research may help to better understand the different responses to psychiatric medication.
Whilst she agrees with the assessment of the dire state of psychiatric care across Africa, De Vries also points out that "some research is better than none at all, as these projects bring opportunities for capacity development -for instance of psychiatric nurses and young researchers -build and consolidate research teams, and foster other, more locally relevant, research that may be more directly translatable to clinical care."
Depression in China
In defence of the genetic approach to psychiatric problems, Jonathan Flint from the University of California at Los Angeles argues that research into depression and anxiety is less generously funded in comparison with cancer and heart disease, although these conditions are comparable in the extent to which they affect people's lives. This, according to Flint, is mainly due to the lack of promising leads for research.
Although depression and anxiety are only modestly shaped by genes, the genetic studies offer the hope of identifying new handles that could then lead to neurochemical work and eventually new drugs. Importantly, research is no longer limited to looking for specifi c genes associated with a condition, but the factors that are in some way associated with conditions, which can also include higher level organisation of the genome, as for instance the copy number variations that have been linked to autism (Curr. Biol. (2011) 21, R571-R573).
Flint's group has conducted a large-scale genetic study of major depression in China, recruiting more than 5,000 Han Chinese women with recurrent depression and a similar number of healthy controls (Depr. Anx. (2016) 33, 1048-1054) . The research established statistical correlations between symptoms and genomic parameters including the copy number of mitochondrial DNA and, separately, the length of the telomeres.
Flint points out that moving genetic research to underappreciated populations can also be helpful for technical reasons. "It is possible to use the different linkage disequilibria structure of populations to aid with genetic mapping to identify genes, as it breaks up regions of linkage disequilibrium." This way, the depression study in China managed to identify two new loci strongly associated with severe depression (Nature (2015) 523, 588-591).
Moreover, Flint says, the widening of the scope can help to identify novel risk loci, as happened with a recent genome-wide association study of schizophrenia patients in China led by Yongyong Shi at Quingdao University, which identifi ed 30 new susceptibility loci (Nat. Genet. (2017 ) 49, 1576 -1583 .
The Stanley Center is also planning to take its psychiatric genetics efforts to China soon, with a schizophrenia project led by institute members Benjamin Neale and Mark Daly and Stanley Center Asia Initiatives director Hailiang Huang. In collaboration with BioX-Shanghai Jiao Tong University and Xi'an Jiaotong University, the researchers plan to collect samples representative of fi ve ethnic populations in six provinces and regions.
Further projects are also planned for Mexico and Finland, whose population has an unusual genetic background separate from the rest of Europe.
The recent expansion of genomics around the world has already helped to better understand past human migrations (Curr. Biol. (2016) 26, R1119-R1121). A fi tting new challenge will be to harness global genomes to understand and heal the human mind.
Michael Gross is a science writer based at Oxford. He can be contacted via his web page at www.michaelgross.co.uk What drew you to biology, particularly to the fi eld of plantmicrobe interactions? It's diffi cult to pinpoint a specifi c experience that sparked my interest in biology. In fact, as a child growing up in a rural village in China, I was generally more interested in how tractors worked. However, even as a child, 'crop protection' was a familiar concept. I understood that in many ways my village relied on agriculture, and that protecting our crops from attack was no trivial matter. The distinct smell of pesticide from the rice fi elds and the removal of cotton bollworm larvae from shoulder-tall cotton plants by hand are memories I've carried with me my whole life. I think these early experiences, and the appreciation I had regarding the importance of agriculture in rural communities, may have had something to do with my interest in plant science later on.
Sheng Yang He
I came to the US to pursue a PhD degree in the late 1980s. Coming from a place where molecular biology was mostly just a scientifi c term found in textbooks, I was quickly mesmerized by the intensive research efforts being poured into cloning various bacterial genes involved in plant-pathogen interactions. In particular, I was intrigued by the mysterious nature of bacterial 'hrp' genes (now called 'type III protein secretion' genes) and 'avr' genes (now called 'effector' genes).
